ARTICLE | Company News
Alfa Wassermann, Norgine sales and marketing update
March 30, 2015 7:00 AM UTC
The U.K.’s NICE issued final guidance recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of episodes of overt hepatic encephalopathy (HE) in adults -- its approved indication in the EU. The guidance is in line with a final appraisal determination (FAD) issued in February (see BioCentury, Feb. 23). ...